Asset

PEGIPANERMIN

INmune Bio Inc. Common stock

Revenue

No revenue reported in loaded filings.

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT04370236phase2_3terminated2020-10-212021-10-13Inmune Bio, Inc.INB03 for the Treatment of Pulmonary Complications From COVID-19

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)